Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SHE:002693)
China · Delayed Price · Currency is CNY 7.89
+0.14 (1.81%)
Feb 4, 2026, 3:04 PM CST
SHE:002693 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 211.44 | 169.49 | 231.06 | 250.33 | 303.56 | 251.48 |
Other Revenue | 4.71 | 4.71 | 4.87 | 24.42 | 16.74 | 17.96 |
| 216.15 | 174.21 | 235.93 | 274.75 | 320.29 | 269.44 | |
Revenue Growth (YoY) | 19.66% | -26.16% | -14.13% | -14.22% | 18.87% | -22.27% |
Cost of Revenue | 106.65 | 84.38 | 82.41 | 94.65 | 87.68 | 65.74 |
Gross Profit | 109.5 | 89.83 | 153.52 | 180.1 | 232.61 | 203.7 |
Selling, General & Admin | 124.04 | 143.19 | 175.23 | 202.13 | 264.62 | 244.34 |
Research & Development | 8.9 | 12.89 | 7.96 | 14.59 | 10.62 | 12.18 |
Other Operating Expenses | 7.06 | 5.35 | 6.02 | 7.71 | 7.03 | 7.18 |
Operating Expenses | 140.13 | 161.6 | 190.35 | 224.34 | 282.23 | 264.06 |
Operating Income | -30.62 | -71.77 | -36.83 | -44.24 | -49.62 | -60.35 |
Interest Expense | -9.77 | -9.23 | -9.58 | -11.19 | -9.03 | -10.01 |
Interest & Investment Income | 0.39 | 0.73 | 2.79 | 4.75 | 4.17 | 2.94 |
Currency Exchange Gain (Loss) | 0.36 | 0.36 | 0.12 | 0.01 | -0.1 | -0.29 |
Other Non Operating Income (Expenses) | -0.19 | -0.04 | -0.18 | -0.05 | -0.81 | -4.63 |
EBT Excluding Unusual Items | -39.83 | -79.96 | -43.69 | -50.71 | -55.39 | -72.34 |
Gain (Loss) on Sale of Investments | -9.74 | -10.09 | -39.85 | -0.06 | - | - |
Gain (Loss) on Sale of Assets | -0.03 | -0.07 | 0.79 | 29.9 | 13.74 | -1.21 |
Asset Writedown | -19.09 | -18.96 | - | -2.1 | - | -9.95 |
Other Unusual Items | 6.34 | 2.9 | 9.78 | 14.09 | 1.29 | 4.72 |
Pretax Income | -62.35 | -106.17 | -72.97 | -8.88 | -40.36 | -78.78 |
Income Tax Expense | -0.41 | 0.1 | -0.99 | -0.38 | 0.45 | 1.17 |
Earnings From Continuing Operations | -61.94 | -106.27 | -71.98 | -8.5 | -40.81 | -79.95 |
Minority Interest in Earnings | 18.95 | 27.96 | 21.23 | 17.51 | 20.48 | 26.62 |
Net Income | -42.99 | -78.3 | -50.74 | 9.01 | -20.33 | -53.33 |
Net Income to Common | -42.99 | -78.3 | -50.74 | 9.01 | -20.33 | -53.33 |
Shares Outstanding (Basic) | 412 | 412 | 423 | 451 | 407 | 410 |
Shares Outstanding (Diluted) | 412 | 412 | 423 | 451 | 407 | 410 |
Shares Change (YoY) | -2.48% | -2.53% | -6.16% | 10.85% | -0.91% | -0.17% |
EPS (Basic) | -0.10 | -0.19 | -0.12 | 0.02 | -0.05 | -0.13 |
EPS (Diluted) | -0.10 | -0.19 | -0.12 | 0.02 | -0.05 | -0.13 |
Free Cash Flow | -7.66 | -65.73 | -37.56 | -7.77 | -8.09 | -62.07 |
Free Cash Flow Per Share | -0.02 | -0.16 | -0.09 | -0.02 | -0.02 | -0.15 |
Gross Margin | 50.66% | 51.56% | 65.07% | 65.55% | 72.62% | 75.60% |
Operating Margin | -14.17% | -41.20% | -15.61% | -16.10% | -15.49% | -22.40% |
Profit Margin | -19.89% | -44.95% | -21.51% | 3.28% | -6.35% | -19.79% |
Free Cash Flow Margin | -3.54% | -37.73% | -15.92% | -2.83% | -2.52% | -23.04% |
EBITDA | 21.47 | -19.43 | 15.84 | 13.3 | 4.71 | -3.26 |
EBITDA Margin | 9.93% | -11.15% | 6.71% | 4.84% | 1.47% | -1.21% |
D&A For EBITDA | 52.1 | 52.34 | 52.67 | 57.54 | 54.33 | 57.09 |
EBIT | -30.62 | -71.77 | -36.83 | -44.24 | -49.62 | -60.35 |
EBIT Margin | -14.17% | -41.20% | -15.61% | -16.10% | -15.49% | -22.40% |
Revenue as Reported | 216.15 | 174.21 | 235.93 | 274.75 | 320.29 | 269.44 |
Advertising Expenses | - | 1.57 | 0.07 | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.